SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: VLAD who wrote (13082)8/12/1998 9:39:00 AM
From: DaiS  Read Replies (1) of 23519
 
Vlad,

>>8)Alibra will be a one dose product. Vivus feels that many patients were initially lost to MUSE because doctor's were starting titrations at the lowest dose and never successfully finishing titration at the highest and most common dose (now they know better and doctors are
instructed to start titration at 500ucgs). >>

I thought this very interesting, as it explains to me the mystery of why recruitment within the first year was probably only around 10-20%

DaiS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News